GSK plc - $GSK STOCK NEWS

GSK announced positive interim results from the DREAMM-8 phase III trial, showing that the combination of belantamab mafodotin, pomalidomide, and dexamethasone (PomDex) significantly reduced the risk of disease progression or death by nearly 50% compared to a standard of care combination in relapsed/refractory multiple myeloma. The median progression-free survival (PFS) was not yet reached at a 21.8-month median follow-up for the belantamab mafodotin combination versus 12.7 months for the bortezomib combination. Additionally, the PFS benefit was observed across all pre-specified subgroups, including high-risk patients. Although a positive trend in overall survival (OS) was noted, it was not statistically significant at this interim analysis. Safety profiles were consistent with known profiles of the individual agents, and common adverse events included neutropenia and ocular symptoms. These findings, presented at the 2024 ASCO Annual Meeting and published in the NEJM, support the potential of belantamab mafodotin in redefining treatment for multiple myeloma at or after first relapse.

GSK announces positive results from the RUBY phase III trial for dostarlimab-gxly in combination with chemotherapy and niraparib for endometrial cancer. The trial shows significant improvements in overall survival and progression-free survival in the overall population and MMRp/MSS population.

GSK announces $2 million commitment in 2024 to boost adult immunization rates and health equity under COiMMUNITY Initiative. New resources and data show adult vaccination rates returning to pre-pandemic levels.

Elsie Biotechnologies, Inc. announces GSK's licensing of their discovery platform after a successful research collaboration, potentially leading to development and commercial milestones. The agreement allows GSK to utilize Elsie's platform for oligonucleotide drug discovery, showcasing the platform's potential for next-generation RNA medicines.

GSK plc has announced that the US FDA has accepted an application to extend the indication of GSK’s adjuvanted respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who are at increased risk for RSV disease. If approved, this would be the first vaccine available to help protect this population. The application is supported by positive results from a phase III trial evaluating the immune response and safety of the RSV vaccine in adults aged 50-59. The US FDA has set a Prescription Drug User Fee Act action date of June 7, 2024.

Elegen and GSK have entered into a multi-year collaboration and licensing agreement, allowing GSK to utilize Elegen's cell-free DNA manufacturing technology in the development of vaccines and medicines. The agreement includes upfront fees, purchase commitments of Elegen's ENFINIA DNA, near-term milestone payments, and a potential equity investment in Elegen by GSK, amounting to up to $35 million in near-term financial and development support and fees. Elegen's ENFINIA DNA, launched in March of last year, delivers NGS-verified, high-complexity, clonal-quality, linear DNA up to 7kb in as fast as seven business days. The technology is expected to save significant time and resources in the development of genetic medicines, potentially including mRNA, cell, and viral gene therapies.

GSK plc (GSK) acquires Aiolos Bio, Inc. (Aiolos) for $1 billion upfront, expanding its respiratory pipeline with AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway. AIO-001 has the potential to redefine the standard-of-care with dosing every six months, reaching a broader portion of asthma patients.

GSK plc (LSE/NYSE: GSK) announced the recipients of the inaugural grant program of the COiMMUNITY Initiative, a multipronged effort to support the design of a more systematic, collaborative, and equitable approach to increasing adult immunization rates in the US. Each grant-funded project is receiving between $50,000 and $175,000 out of a total $1 million in funding to address long-standing barriers to adult immunization in the US.

GSK plc (LSE/NYSE: GSK) Launches Mapping Myelofibrosis Initiative in Partnership with Thom Filicia to Raise Awareness for Myelofibrosis (MF) - a Complex Blood Cancer Affecting 25,000 People in the U.S.